GlassScriptPhysician profile
Charles Jacob Brown
NPI 1235155250
$3,478.28
in general payments reported to CMS, 2019-2025
30 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $112 · 2021: $249 · 2022: $784 · 2023: $724 · 2024: $604 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.16 |
| Education | $280.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.34 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $491.81 | 2021-2025 | Tremfya |
| Merz North America, INC. | $312.91 | 2021-2022 | |
| Galderma Laboratories, L.P. | $269.78 | 2019-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $188.13 | 2022-2025 | Sotyktu |
| Pfizer INC. | $148.89 | 2019-2024 | |
| Ucb, INC. | $140.54 | 2022-2025 | Cimzia, Bimzelx |
| Mayne Pharma Commercial LLC | $139.95 | 2019-2023 | |
| Leo Pharma INC. | $139.73 | 2021-2022 | |
| Dermavant Sciences, INC. | $122.60 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $110.19 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $102.48 | 2021-2025 | |
| Biofrontera INC. | $82.15 | 2022-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $80.03 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $78.32 | 2021-2025 | Libtayo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $73.70 | 2024-2025 | Vtama |
| Amgen INC. | $43.46 | 2020-2025 | Otezla |
| Sandoz INC. | $41.19 | 2023-2024 | Hyrimoz |
| Incyte Corporation | $38.67 | 2024 | Opzelura |
| Botanix Sb INC | $37.03 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $22.56 | 2023 | Idacio |
| Organogenesis INC. | $18.10 | 2025 | Novachor |
| Almirall LLC | $18.02 | 2021 | |
| Lilly USA, LLC | $17.60 | 2025 | Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.35 | 2020 | |
| Genentech USA, INC. | $16.13 | 2023 | Erivedge |
| Vyne Pharmaceuticals INC. | $15.07 | 2021 | |
| Verrica Pharmaceuticals INC. | $14.43 | 2023 | Ycanth |
| Mission Pharmacal Company | $13.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.